Fiche du document
2011
- doi: 10.1126/scitranslmed.3001863
- issn: 1946-6234
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1126/scitranslmed.3001863
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/21508308
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1946-6242
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_F0E24EC6F0270
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
People Man Humanity (Human beings) Human race Mankind Homo sapiens Humankind Humans Controlled clinical trials Randomized clinical trials Trials, Clinical Patient trials of new treatmentsCiter ce document
L. Corey et al., « HIV-1 vaccines and adaptive trial designs. », Serveur académique Lausannois, ID : 10.1126/scitranslmed.3001863
Métriques
Partage / Export
Résumé
Developing a vaccine against the human immunodeficiency virus (HIV) poses an exceptional challenge. There are no documented cases of immune-mediated clearance of HIV from an infected individual, and no known correlates of immune protection. Although nonhuman primate models of lentivirus infection have provided valuable data about HIV pathogenesis, such models do not predict HIV vaccine efficacy in humans. The combined lack of a predictive animal model and undefined biomarkers of immune protection against HIV necessitate that vaccines to this pathogen be tested directly in clinical trials. Adaptive clinical trial designs can accelerate vaccine development by rapidly screening out poor vaccines while extending the evaluation of efficacious ones, improving the characterization of promising vaccine candidates and the identification of correlates of immune protection.